We have published an application note that presents an optimized method for HPLC separation of semaglutide and liraglutide. This method is developed under both acidic and alkaline conditions employing NanoPak-C All-Carbon reverse phase media.
Semaglutide and Liraglutide are peptide drugs that mimic the natural hormone glucagon-like peptide-1 (GLP-1). These drugs trigger the production of insulin, which decreases blood sugar (glucose) levels. They also reduce the amount of sugar released into the blood and slow down digestion. Thus, these drugs are used to treat type 2 diabetes and promote weight loss.
Separation and purification of semaglutide and liraglutide are essential to meet drug quality requirements. Optimizing the separation process requires careful consideration of several factors. These include selecting the appropriate column media, mobile phase pH and composition (percentage of aqueous and organic phase), flow rate, temperature, and utilizing techniques like gradient elution.
NanoPak-C All-Carbon reverse phase media offers benefits such as pH stability and unique selectivity beneficial for the sustainable separation of peptides. It offers full flexibility in method development for the separation and purification of semaglutide and liraglutide.
Download our application note on the Separation of Semaglutide and Liraglutide on the NanoPak-C All Carbon HPLC column.
s
Get in touch to discuss how we can support your GLP-1 receptor analysis. Please email us at inquiry@millennialscientific.com, call us at 855 388 2800, or fill in our online form.
Comments